Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (1)

2023

  1. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

    Frontiers in Immunology, Vol. 14